NCT04983732View on ClinicalTrials.gov

A Bioavailability Study of FL-101 in Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

September 11, 2021

Primary Completion Date

May 5, 2022

Study Completion Date

May 5, 2022

Conditions

Healthy Subjects

Interventions

DRUG

FL-101-Intravenous

150 mg administered via the IV route

DRUG

FL-101-Subcutaneous

150 mg administered via the SC route

Trial Locations (1)

56529

Axis Clinicals, Dilworth

Sponsors

Lead Sponsor

Flame Biosciences

All Listed Sponsors

lead

Flame Biosciences

INDUSTRY